Anastrozole is a drug originally developed for postmenopausal women with breast cancer, but doctors now prescribe it off-label to men for a handful of hormone-related conditions. Its primary job is to block aromatase, the enzyme that converts testosterone into estrogen. By dialing down estrogen production, anastrozole can shift a man’s hormonal balance in ways that help with low testosterone, fertility problems, and a few other situations. The drug is not FDA-approved for any male indication, though, and that gap between common clinical use and formal approval creates real questions about safety and monitoring that are worth understanding.
How Anastrozole Works in a Male Body
Men produce estrogen too, just in smaller amounts than women. A portion of every man’s circulating testosterone gets converted into estradiol (the main form of estrogen) by the aromatase enzyme, which is active in fat tissue, the brain, bone, and other organs. When estradiol climbs too high relative to testosterone, it can cause symptoms like breast tissue swelling, mood changes, water retention, and sexual dysfunction. It also sends a signal to the brain’s pituitary gland that enough sex hormones are circulating, which dials back the release of the hormones (LH and FSH) that tell the testes to produce testosterone and sperm.
Anastrozole interrupts this conversion. By blocking aromatase, less testosterone gets turned into estradiol. The result is a drop in estrogen and, in men who still have functioning testes, a rise in testosterone because the pituitary gland senses lower estrogen and ramps up its signaling. That dual effect, lower estrogen and higher testosterone, is the reason anastrozole shows up across several different clinical scenarios in men.
Low Testosterone and Hypogonadism
One of the most common reasons a man ends up on anastrozole is low testosterone, sometimes called hypogonadism. In men whose testes still respond to pituitary signals but whose testosterone-to-estrogen ratio has drifted out of range, anastrozole can nudge the system back toward normal without shutting down the body’s own hormone production. This is an important distinction from testosterone replacement itself, which delivers the hormone externally and typically suppresses the body’s own production and sperm output.
A study of overweight and obese subfertile men with low testosterone found that five months of anastrozole raised mean testosterone from about 271 to 412 ng/dL while cutting estradiol roughly in half, from 32 to about 16 pg/mL.1PubMed Central. Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m² That kind of improvement matters clinically for men sitting in the gray zone of low-normal testosterone who have symptoms like fatigue, low libido, or difficulty building muscle. The approach is especially attractive for younger men or men who want to preserve fertility, since testosterone replacement would suppress sperm production.
Controlling Estrogen During Testosterone Therapy
When a man goes on testosterone replacement therapy (TRT), his body gains extra substrate for aromatase to work on, so estradiol levels often rise alongside testosterone. For some men this causes no noticeable problems, but others develop symptoms: tender or swollen breast tissue, bloating, mood instability, or worsening of sleep apnea. In these cases, doctors may add anastrozole to keep estradiol in check.
Research on men receiving testosterone therapy who were then given anastrozole found that median estradiol levels dropped from 65 pg/mL to 22 pg/mL, while testosterone levels stayed essentially unchanged.2Elsevier / Oxford University Press (Sexual Medicine). The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy That is a meaningful estrogen reduction without sacrificing the testosterone benefit the man went on therapy to get in the first place. Another approach involves combining anastrozole directly with subcutaneous testosterone implants, where low-dose anastrozole released from the implant kept estradiol low throughout the treatment cycle and prevented estrogen-related side effects.3PubMed Central. Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy
A separate study of men receiving testosterone pellet implants found that adding anastrozole kept both total and free testosterone significantly higher beyond four months compared to pellets alone, and extended the time before reimplantation was needed from about 128 days to 198 days.4PubMed Central / Wiley Online Library. Coadministration of anastrozole sustains therapeutic testosterone levels in hypogonadal men undergoing testosterone pellet insertion For men who dislike frequent clinic visits for pellet reinsertion, that practical benefit adds up.
Male Infertility
This is where anastrozole arguably earns its most distinctive role in men’s health. Fertility drugs for men are limited, and anastrozole’s ability to raise FSH and LH without introducing external hormones makes it useful for men with low sperm counts tied to a poor testosterone-to-estrogen ratio. Because the pituitary responds to falling estrogen by pumping out more FSH (the hormone that drives sperm production in the testes), anastrozole can improve semen parameters in a way that testosterone replacement cannot.
In a cohort of subfertile men with low testosterone and low sperm counts, anastrozole improved sperm concentration from about 7.8 to 14.2 million per mL and total motile count from 12.6 to 17.7 million over five months.1PubMed Central. Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥25 kg/m² A separate study found that over 95% of treated men saw their testosterone go up and estradiol go down, with sperm concentration and total motile counts improving in the large majority of participants.5PubMed Central. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men The magnitude of improvement in motile sperm count correlated with how much the testosterone-to-estradiol ratio shifted, which supports the idea that the hormonal rebalancing is driving the fertility benefit.
Some fertility specialists pair anastrozole with clomiphene citrate, another off-label fertility drug for men that works through a different mechanism. A multi-center retrospective study found that the combination led to normalization of sperm parameters in 43% of men, compared to 25% on anastrozole alone, with a marked improvement in total motile sperm count in the combination group.6PubMed Central. Combination clomiphene citrate and anastrozole duotherapy improves semen parameters in a multi-institutional, retrospective cohort of infertile men These numbers are not blockbuster, but for couples trying to conceive without jumping straight to assisted reproduction, they represent a genuine and relatively low-cost option.
Increasing Height in Adolescent Boys
This use might surprise people who only associate anastrozole with adult men. In growing boys, estrogen is the hormone that signals the growth plates in long bones to close, ending the period of vertical growth. By slowing that closure, anastrozole can extend the window during which growth hormone does its job. The result is added height potential.
A randomized, placebo-controlled trial of adolescent boys on growth hormone therapy found that adding anastrozole for two to three years slowed bone age advancement dramatically. After three years, bone age had advanced only about 2.5 years in the anastrozole group compared to 4.1 years in the placebo group. Predicted adult height increased by roughly 6.7 cm in the anastrozole group at three years, compared to about 1 cm in the placebo group, all while pubertal progression remained normal.7Academic Research Platform / Scopus. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years
Another study confirmed this picture, finding that when boys received anastrozole alongside growth hormone for at least two years, mean adult height was about 3 cm greater than in boys who received growth hormone alone.8Europe PMC. The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy This is not a routine treatment, and pediatric endocrinologists weigh the height benefit against the unknowns of suppressing estrogen during development. But in cases of short stature where the growth plates are closing too fast, it is a tool that has real data behind it.
Gynecomastia
Gynecomastia, the development of breast tissue in males, is one of the most intuitive reasons you might expect an estrogen-blocking drug to help. Excess estrogen relative to androgens stimulates breast tissue growth, so blocking the enzyme that produces estrogen seems like a logical fix. In practice, though, the evidence for anastrozole in this setting has been underwhelming.
A randomized, double-blind, placebo-controlled trial in boys with pubertal gynecomastia found no significant difference between anastrozole and placebo. About 38.5% of boys in the anastrozole group had at least a 50% reduction in breast volume, compared to 31.4% in the placebo group, a gap that was not statistically meaningful.9PubMed Central. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial The high placebo response rate reflects the fact that pubertal gynecomastia resolves on its own in many cases. For adult men with persistent gynecomastia, the picture is similarly mixed: doctors sometimes prescribe anastrozole early in the course when the tissue is still largely glandular and not yet fibrotic, but once the breast tissue has matured into firm, fibrous tissue, no medication is likely to reverse it and surgery becomes the main option.
Bodybuilding and Steroid Cycles
Anastrozole is widely used in the bodybuilding world, though virtually none of this use happens under medical supervision. Men who take supraphysiological doses of anabolic steroids convert a significant share of those androgens into estrogen, and the resulting estradiol spike can cause gynecomastia, water retention, and high blood pressure. To counteract this, many steroid users take anastrozole (or a similar aromatase inhibitor) during their cycles.
An analysis of online bodybuilding forums found that steroid users routinely consume aromatase inhibitors to “fight against androgen aromatisation” and use related drugs like tamoxifen to attempt to restart their natural hormone axis after a steroid cycle.10Elsevier / PubMed Central / Therapie. Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions The doses and protocols described in these communities are not derived from clinical evidence and are often guided by anecdotal reporting from other users. This matters because, as the sections below on bone loss, lipid changes, and estrogen over-suppression make clear, pushing estrogen too low carries its own set of health consequences. Men using anastrozole in this context are typically doing so without blood work, without physician oversight, and without a clear understanding of the downstream risks.
The Prostate Cancer Question
Given that anastrozole is an anti-cancer drug in women, a reasonable question is whether it has any role in prostate cancer. Researchers have explored this, and the answer so far is no. A trial of anastrozole in men with advanced prostate cancer found that no patient experienced an objective response or disease stabilization as measured by PSA levels or tumor size.11Wiley Online Library. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma Prostate cancer is primarily an androgen-driven disease, so a drug that raises testosterone while lowering estrogen is working in exactly the wrong direction. This finding also serves as a caution: men with a history of prostate cancer or elevated PSA should discuss the implications of any testosterone-raising therapy with their doctor.
Bone Loss From Estrogen Suppression
Estrogen is not just a reproductive hormone. In both sexes, it plays a central role in maintaining bone density. Osteoclasts (the cells that break down bone) are held in check partly by estrogen signaling, so when you suppress estrogen, bone breakdown accelerates. This is the most well-documented long-term risk of anastrozole.
The clearest data comes from the large ATAC trial in women, which found that five years of anastrozole use led to a roughly 6% drop in lumbar spine bone mineral density and about a 7% drop at the total hip, while the comparison group on tamoxifen actually gained bone density at both sites.12National Institutes of Health. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial This trial studied postmenopausal women, who already have lower estrogen than men, so the bone loss in men taking typical low doses may be less dramatic. Still, the mechanism is the same regardless of sex. Men who use anastrozole long-term, especially those who are older, have low body weight, or have other osteoporosis risk factors, should have their bone density monitored. A review of aromatase inhibitor use in males noted that while the drugs are effective for several conditions, long-term safety has not been established and routine use is not yet recommended.13Europe PMC. Aromatase inhibitors in men: effects and therapeutic options
Effects on Cholesterol and Cardiovascular Risk
Estrogen has a protective effect on the cardiovascular system in part because it helps maintain favorable cholesterol levels. Suppressing estrogen with anastrozole can shift the lipid profile in directions that raise concern. A systematic review and meta-analysis of randomized controlled trials found that anastrozole lowered total cholesterol modestly (especially when baseline levels were already high) and reduced HDL cholesterol, the “good” cholesterol, when treatment lasted more than three months. It had no significant effect on LDL cholesterol or triglycerides.14ScienceDirect. The Effect of Anastrozole on the Lipid Profile: Systematic Review and Meta-analysis of Randomized Controlled Trials
The HDL reduction is the more worrying finding. Lower HDL is consistently associated with higher cardiovascular risk, and while the magnitude of the drop was small in absolute terms (about 1.7 mg/dL in studies lasting over three months), the clinical relevance depends on the individual’s baseline risk. A broader review noted that the evidence on anastrozole and lipids has been mixed across studies, with some showing little effect and others showing adverse shifts.15Europe PMC. The effects of aromatase inhibitors on lipids and thrombosis For men who already have unfavorable lipid profiles or cardiovascular disease, this is another reason to monitor blood work and weigh the benefit against the risk.
Cognitive Effects
Estrogen has neuroprotective properties. It supports synaptic connections in the brain and plays a role in memory and concentration. So it is reasonable to ask what happens to cognition when you suppress it. Most of the data comes from studies in women, but the underlying biology is not sex-specific.
A study tracking cognitive function during anastrozole therapy observed a pattern of decline in working memory and concentration during the first six months. Patients on anastrozole alone showed a dip in visual working memory (which partially recovered between six and twelve months) followed by another decline between twelve and eighteen months. Concentration followed a similar up-and-down trajectory.16Wiley Online Library (Cancer). Patterns of Change in Cognitive Function with Anastrozole Therapy The researchers attributed the early decline to the sudden drop in estrogen and its downstream effects on brain metabolism and synaptic connectivity.
Whether men taking much lower doses for shorter durations experience the same cognitive patterns is an open question. The women in the study were on standard oncology doses for extended periods, and the effect sizes were relatively small. But the finding is a reason to take seriously any complaints of brain fog or difficulty concentrating in men on anastrozole, rather than dismissing them.
The Risk of Crashing Estrogen Too Low
The goal with anastrozole in men is to reduce estrogen, not to eliminate it. Men need some estradiol for bone health, cardiovascular protection, brain function, libido, and even healthy joint lubrication. When estrogen drops too far, men can experience fatigue, joint pain and stiffness, dried-out skin, diminished sex drive (paradoxically, given that the testosterone is often going up), depression, and accelerated bone loss.
This is a real problem in practice, especially when men take anastrozole without regular blood monitoring. The standard clinical approach is to start with a low dose, typically 0.5 mg to 1 mg taken two or three times per week rather than daily, and then adjust based on estradiol levels. Doctors generally target an estradiol range rather than trying to push it as low as possible. When the drug is used alongside testosterone therapy, the feedback loop between the two hormones means that dialing estrogen down too aggressively can produce symptoms that are every bit as unpleasant as the high-estrogen symptoms the man started with.
Genetic Variation in Drug Response
Not everyone metabolizes anastrozole the same way, and genetic differences in the aromatase gene itself (CYP19A1) can influence both how well the drug works and what side effects it causes. Research in breast cancer patients found that certain variants in the CYP19A1 gene were strongly associated with whether patients developed joint pain on anastrozole, and other variants correlated with cancer recurrence rates.17Europe PMC. Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients While this data comes from women, the same gene encodes the same enzyme in men. A man who experiences particularly severe joint pain or unexpectedly poor hormonal response to anastrozole may have a genetic profile that affects how his body handles the drug. Pharmacogenomic testing is not standard practice for anastrozole prescriptions yet, but the science suggests it could eventually help personalize dosing.
Joint Pain and Musculoskeletal Complaints
Joint pain is one of the most commonly reported side effects of anastrozole across all populations. In the oncology literature, arthralgia affects a substantial fraction of patients and is one of the leading reasons women discontinue the drug. Men tend to take lower doses for shorter periods, which probably reduces the incidence, but the complaint still surfaces in clinical practice. The mechanism ties back to estrogen’s role in joint tissue: estrogen helps regulate inflammation and fluid balance in the synovial membranes that line joints. Pull estrogen down, and you can get stiffness, aching, and discomfort that feels a lot like early arthritis.
For men who develop joint symptoms on anastrozole, the first question is whether the dose can be lowered or the dosing schedule spaced out further. In many cases, cutting back is enough to resolve the issue while still achieving the desired hormonal shift. If joint pain persists, switching to a different aromatase inhibitor or discontinuing the drug entirely may be necessary. The reversibility of the symptom after stopping the drug is generally good, though it can take weeks to fully resolve.
Why It Remains Off-Label for Men
Anastrozole has been FDA-approved since 1995, but exclusively for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Every use in men is off-label. That does not mean the uses are unsupported, off-label prescribing is common and legal when there is reasonable clinical evidence, but it does mean that no pharmaceutical company has invested in the large-scale trials in male populations that the FDA requires for formal approval. The drug is inexpensive and generic, which removes the financial incentive for a manufacturer to fund those trials.
The practical consequence is that dosing protocols for men are based on smaller studies, clinical experience, and extrapolation from women’s data rather than the kind of large, long-term randomized trials that back most approved medications. Monitoring is therefore more important than it might be with a fully approved therapy: regular blood draws to check estradiol, testosterone, lipids, and possibly bone density scans for long-term users are the standard of care among physicians who prescribe it frequently. Men who obtain anastrozole without a prescription, whether from online pharmacies or underground sources for bodybuilding purposes, are skipping that safety net entirely and taking on risks they may not fully appreciate.